

OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")

Clinical trial to evaluate the effect of WellBiome® on surgical outcomes and NHS cost savings

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings.

A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes.

This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotics like WellBiome in improving health outcomes and cost savings.

WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: -

- Nourishes beneficial bacteria throughout the entire gut to improve gut health
- Contributes to improved bone health by aiding the absorption of essential minerals
- Contributes to normal muscle function, including heart muscle
- Supports normal brain health function and memory
- Contributes to normal psychological function
- Supports cardiovascular health
- Contributes to a reduction of tiredness and fatigue

Gut health is a growing health trend around the world with more than 80 percent of consumers in China, the United Kingdom, and the United States considering gut health to be important, and over 50 percent anticipating making it a higher priority in the next two to three years [The top wellness trends in 2024 | McKinsey](#). WellBiome was developed to meet this need and can be purchased from www.optibiotix.online with a 30% discount using the OPTI30 discount code.

Stephen O'Hara, CEO of OptiBiotix, commented:

"Prebiotics like WellBiome are a growing trend for products which improve gut, immune, and general health. More recently the systemic anti-inflammatory effect of prebiotics has been suggested to improve post-surgical outcomes. This NHS study by Hull University Hospitals Trust has been designed to evaluate the potential of taking WellBiome as a preoperative supplement on cardiac surgery patients on the length of time patients spend in ICU, length of hospital stay, the impact on post operative complications, and potential NHS cost savings. If successful it could lead to WellBiome becoming the standard of care for NHS patients undergoing surgery".

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say by subscribing to the new website to get regular updates: <https://optibiotix.com/auth/signup>

View the full announcement and submit questions to management via our website: <https://optibiotix.com/link/PbLd4e>

For further information, please contact: OptiBiotix Health plc
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

www.optibiotix.com

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envision", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSEIFWDEMSESE